CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.
  
  

  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with cancer.
  
  LEARNING OBJECTIVES

  • Consider the scientific justification for the use of antibody-drug conjugates (ADCs) as a therapeutic approach for patients with various tumor types, and recall the targets, structural components and mechanisms of activity of different clinically available and investigational agents in this class.
  • Appraise available clinical research data with novel ADCs for various cancers, and consider the current and potential role of these approaches in routine clinical care.
  • Appreciate the pathophysiology and severity of common and rare toxicities associated with ADCs employed in the treatment of different tumor types.
  • Understand the incidence of toxicities observed in pivotal trials evaluating novel ADCs, and educate patients about to commence therapy with these approaches regarding the potential development of these adverse events and what to do if they are suspected.
  • Recall strategies commonly employed to identify, manage and mitigate resultant toxicities of anticancer treatment with ADCs, and use this information to appropriately intervene for patients in whom these side effects are suspected or diagnosed.
  • Understand the role of multidisciplinary specialists such as cardiologists, ophthalmologists and other medical professionals in the diagnosis and management of ADC-associated toxicities, and effectively educate patients regarding the potential need for and importance of specialty referral.

  ACCREDITATION STATEMENT
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: This educational activity for 2.25 contact hours is provided by RTP during the period of April 2025 to April 2026.
  
  This activity is awarded 2.25 ANCC pharmacotherapeutic contact hours.
  
  Video Program: This educational activity for 1.75 contact hours is provided by RTP during the period of April 2025 to April 2026.
  
  This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.
  
  ONCC/ILNA CERTIFICATION INFORMATION
  The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2025/ADCs/ILNA.
  
  ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  FOR SUCCESSFUL COMPLETION
  Audio Program: This NCPD activity consists of an audio component. To receive credit, the participant should review the NCPD information, listen to the MP3s, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONS2025/ADCsPanTumor/NCPD. The corresponding video program is available as an alternative at ResearchToPractice.com/ONS2025/ADCsPanTumor/Video.
  
  Video Program: This NCPD activity consists of a video component. To receive credit, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONS2025/ADCsPanTumor/Video/NCPD. The corresponding audio program is available as an alternative at ResearchToPractice.com/ONS2025/ADCsPanTumor.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Marianne J Davies, DNP, ACNP, AOCNP, FAAN
  Program Manager, Care Signature
  Oncology Service Line, Yale New Haven Health
  Oncology Nurse Practitioner-Senior APP II
  Yale Cancer Center
  Smilow Cancer Hospital at Yale New Haven
  Associate Professor
  Yale University School of Nursing
  New Haven, Connecticut
  
  No relevant conflicts of interest to disclose.
  
  Edward B Garon, MD, MS
  Professor
  Director, Thoracic Oncology Program
  Director, Signal Transduction and Therapeutics Research Program
  David Geffen School of Medicine at UCLA
  Jonsson Comprehensive Cancer Center
  Los Angeles, California
  
  Advisory Committees and Consulting Agreements: AbbVie Inc, Arcus Biosciences, ArriVent Biopharma, AstraZeneca Pharmaceuticals LP, Atreca, Black Diamond Therapeutics Inc, BridgeBio, Bristol Myers Squibb, EMD Serono Inc, Gilead Sciences Inc, Hookipa Pharma Inc, I-Mab Biopharma, LianBio, Lilly, Merck, Merus, Novartis, Nuvalent, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Sensei Biotherapeutics, Strata Oncology, Sumitomo Dainippon Pharma Oncology Inc, Summit Therapeutics, Synthekine; Contracted Research: ABL Bio, ArriVent Biopharma, AstraZeneca Pharmaceuticals LP, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Iovance Biotherapeutics, Lilly, Merck, Mirati Therapeutics Inc, Novartis, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Synthekine, TILT Biotherapeutics; Sponsored Independent Medical Education: Daiichi Sankyo Inc; Travel: A2 Bio, Novartis.
  
  Marissa Marti-Smith, DNP, APRN, AGNP-C, AOCNP
  Nurse Practitioner
  Texas Oncology-Baylor Charles A Sammons Cancer Center
  Dallas, Texas
  
  Speakers Bureaus: Biotheranostics Inc, Stemline Therapeutics Inc; Nonrelevant Financial Relationships: ASCO Advantage, Clinical Education Alliance.
  
  Tiffany A Traina, MD, FASCO
  Vice Chair, Department of Medicine
  Section Head, Triple-Negative Breast Cancer Clinical Research Program
  Associate Attending Physician
  Breast Medicine Service
  Memorial Sloan Kettering Cancer Center
  Associate Professor
  Weill Cornell Medical College
  New York, New York
  
  Advisory Committees and Consulting Agreements: Aktis Oncology, AstraZeneca Pharmaceuticals LP, BioNTech SE, Daiichi Sankyo Inc, Ellipses Pharma, Exact Sciences Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Merck, Pfizer Inc, Stemline Therapeutics Inc, TerSera Therapeutics LLC, Veracyte Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, BioNTech SE, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Pfizer Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
  
  RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.
  
  Release date: April 2025
  Expiration date: April 2026
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.